(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Cytokinetics (CYTK) reported a Q2 net loss late Thursday of $0.23 per diluted share, compared with a loss of $0.86 a year earlier. Analysts polled by...
...
| Address | 350 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.650.624.3000 |
| Number of Employees | 130 |
| Recent SEC Filing | 08/08/2022 4 |
| President, Chief Executive Officer & Director | Robert I. Blum |
| Vice President-Development Operations | Eric Terhaerdt |
| Chief Financial Officer & Senior Vice President | Ching W. Jaw |
| Executive Vice President-Research & Development | Fady Ibraham Malik |
| Price Open | $50.30 |
| Previous Close | $49.47 |
| 52 Week Range | $29.10 - 54.74 |
| Market Capitalization | $4.7 B |
| Shares Outstanding | 94.1 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 11/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.57 |
| Beta vs. S&P 500 | N/A |
| Revenue | $31.5 M |
| Net Profit Margin | -142.85% |
| Return on Equity | -119.86% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
